Comment: reasons for early abacavir discontinuation in HIV-infected patients

1. Peyriere H Guillemin V Lotthe A Baillat V Fabre J Favier C Reasons for early abacavir discontinuation in HIV-infected patients. Ann Pharmacother 2003;37:1392–7. DOI 10.1345/aph.1C523.

2. Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther 2002;24:1502–14.

3. Léautez S Esnault J Billaud E Ferre V Raffi F. Efficacy and tolerance of abacavir-containing antiretroviral regimens in a cohort of 145 HIV+ patients (abstract 239). Presented at: 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, 2001.

4. Katlama C Fenske S Gazzard B Lazzarin A Clumeck N Mallolas J TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003;4:79–86.

5. Bersoff-Matcha SJ Miller WC Aberg JA van der Horst C Hamrick J Jr Powderly WG Sex differences in nevirapine rash. Clin Infect Dis 2001;32:124–9.

6. Thompson M , the AIDS Research Consortium of Atlanta. HEART: helping enhance adherence to antiretroviral therapy (NZT4006). Interruptions in abacavir dosing are not associated with increased risk of hypersensitivity in the HEART study (NZT4006) (abstract L-14). Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000.